Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Kaufman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Virology|August 1, 1992
The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformationW H Walker, B Stein, P A Ganchi, et al.
Journal of Hematotherapy|October 1, 1995
Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
British Journal of Cancer|April 19, 2014
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHERD A Yardley, D Tripathy, A M Brufsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Journal of Immunological Methods|February 27, 2001
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.
Journal of Immunological Methods|February 27, 2001
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivoP K Wallace, P A Kaufman, L D Lewis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neuT Schwaab, L D Lewis, B F Cole, et al.
Breast Cancer Research and Treatment|June 11, 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participantsAnn H Partridge, A C Wolff, P K Marcom, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Virology|August 1, 1992
The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformationW H Walker, B Stein, P A Ganchi, et al.
Journal of Hematotherapy|October 1, 1995
Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
British Journal of Cancer|April 19, 2014
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHERD A Yardley, D Tripathy, A M Brufsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Journal of Immunological Methods|February 27, 2001
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.
Journal of Immunological Methods|February 27, 2001
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivoP K Wallace, P A Kaufman, L D Lewis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neuT Schwaab, L D Lewis, B F Cole, et al.
Breast Cancer Research and Treatment|June 11, 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participantsAnn H Partridge, A C Wolff, P K Marcom, et al.
Pageof 2